COX-2-IN-55 

COX-2-IN-55 (compound 1) is an orally active, Celecoxib (HY-14398)-based analog with broad-spectrum anticancer activity and weak COX-2 inhibition. COX-2-IN-55 specifically inhibits SERCA2, increases caspase-3 cleavage and DR5 levels, thereby activating GRP78 and inhibiting the development of triple-negative breast cancer (TNBC). COX-2-IN-55 can also downregulate the levels of angiogenic markers VEGF-α and IL-8, inhibiting the formation of microvessels^[1].

COX-2-IN-55 (compound 1) inhibits the viability of MDA-MB-231 cells, MDA-MB-468 cells, 4T1 cells, T47D cells, and MCF-7 cells with EC50 of 14.99 μM, 14.26 μM, 11.23 μM, 17.3 μM, and 25.02 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

COX-2-IN-55 (25 mg/kg/day, 50 mg/kg/day; po; 28 days) exhibited significant antitumor properties in the MDA-MB-231 xenograft nu/nu mouse model, causing up to 85% tumor regression^[1].
At a dose of 100 mg/kg/day COX-2-IN-55, no significant biochemical or histological toxicity was observed in mice after 48 days of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

486.51

C₂₄H₂₁F₃N₄O₂S

2649115-80-8

O=S(NC1=CC(N)=CC=C1)(C2=CC=C(N3N=C(C(F)(F)F)C=C3C4=C(C)C=CC(C)=C4)C=C2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Louie Stan, et al. Methods, compounds and compositions for the treatment of cancer by inhibiting notch-1 maturation. World Intellectual Property Organization, WO2021113605 A1. 2021-06-10.